HXN-2001
/ Earendil Labs
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Design and development of a biparatopic antibody-drug conjugate against CDH17
(AACR 2026)
- "The ADCs showed selective cytotoxicity towards multiple tumor cell lines with varying levels of CDH17 expression in vitro, and potently inhibited the growth of CDH17-expressing tumor xenografts in animal models. Together, these findings indicate that our lead biparatopic anti-CDH17 ADC is a promising candidate for the treatment of cancers that overexpress CDH17."
ADC • IO biomarker • Oncology • Pancreatic Cancer • Solid Tumor • CDH17
1 to 1
Of
1
Go to page
1